Why Globant Stock Is Back on Investors’ Radar
Globant (GLOB) is drawing fresh attention after two new partnerships: one applying its enterprise AI platform to cancer drug discovery with PharmaMar, and another expanding its role in global payments integration with Adyen.
For you as an investor, these moves sit at the intersection of healthcare AI and financial services technology, two areas where large clients often demand complex, long term solutions rather than one off projects.
See our latest analysis for Globant.
Despite the new AI partnerships in healthcare and payments, Globant’s share price has had a tough run, with a 90 day share price return of a 34% decline and a 1 year total shareholder return of a 62% decline, which suggests recent news is arriving against a backdrop of weaker sentiment.
If you like the AI angle behind Globant’s recent moves, it can be worth widening your search to other opportunities in this space through 34 AI small caps
With Globant trading at $44.52 and sitting at a 55% intrinsic discount and a 63% discount to the current analyst price target, the key question is whether this weakness offers a buying opportunity or whether markets already reflect future growth.
Most Popular Narrative: 39.3% Undervalued
At $44.52, the most widely followed narrative sees Globant trading well below an estimated fair value of $73.36, with that gap anchored in long term cash flow assumptions.
The rapid adoption of AI and generative AI across industries is increasing the complexity of enterprise technology environments, driving greater demand for specialist partners to design, implement, and maintain tailored AI solutions. Globant's Enterprise AI platform, AI pods subscription model, and recent multiyear partnership wins (e.g., OpenAI, AWS) position the company to capture a greater share of this market, potentially affecting both revenue and long-term margins as more high-value, recurring AI engagements convert in the pipeline.
Curious what has to happen for that fair value to hold up? The narrative leans heavily on faster earnings compounding, firmer margins, and a premium earnings multiple. The exact mix might surprise you.
Result: Fair Value of $73.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, persistent demand softness and questions around the scalability of the AI pod model could still pressure growth expectations and challenge the 39.3% undervaluation narrative.
Find out about the key risks to this Globant narrative.
Another Angle on Valuation: Earnings Multiple Tells a Different Story
While the SWS model sees Globant trading at a 54.8% discount to estimated fair value, the market is assigning a P/E of 18.7x, above the 11.2x peer average but below the US IT industry at 19.4x and the fair ratio of 30.3x.
That mix of a higher peer multiple but a lower fair ratio benchmark suggests the market is cautious on near term fundamentals yet still leaving room for sentiment to shift if earnings progress aligns with expectations. The key question for investors is which signal to put more weight on.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Uncertain whether the current mix of weak sentiment and AI potential really adds up in your view? Move quickly, review the data for yourself, and weigh both sides with 2 key rewards and 2 important warning signs
Ready to uncover more opportunities?
If Globant has caught your eye, do not stop here. Expand your watchlist now or you risk missing companies that better match your risk and return preferences.
- Target resilient ideas by scanning companies with strong finances using the solid balance sheet and fundamentals stocks screener (39 results).
- Hunt for potential bargains that combine quality and pricing support through the 62 high quality undervalued stocks.
- Strengthen your income stream by checking businesses with higher yields and sturdy profiles via the 12 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com